Rare diseases
Investigational molecules
Locations
Study of etentamig and iberdomide treatment for patients with relapsed or refractory multiple myeloma
FranceStudy on the Safety and Efficacy of Cevostamab with Lenalidomide or Iberdomide for Patients with High-Risk or Relapsed Multiple Myeloma
FranceStudy of Iberdomide and Isatuximab for Maintenance Therapy in Patients with Newly Diagnosed Multiple Myeloma After Stem-Cell Transplantation
AustriaStudy Comparing Iberdomide and Lenalidomide for Maintenance Therapy After Stem Cell Transplant in Patients with Newly Diagnosed Multiple Myeloma
AustriaStudy of ixazomib, iberdomide and dexamethasone combination in elderly patients with first relapse of multiple myeloma
FranceStudy on Multiple Myeloma Treatment with Isatuximab, Lenalidomide, and Carfilzomib for Patients Under 66 Eligible for Stem Cell Transplant
BelgiumStudy on Iberdomide, Cyclophosphamide, and Dexamethasone for Patients with Relapsed or Refractory Multiple Myeloma
The NetherlandsStudy comparing iberdomide, daratumumab and dexamethasone versus daratumumab, bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma
AustriaStudy on Iberdomide and Dexamethasone, Alone or with Drug Combination, for Newly Diagnosed Multiple Myeloma Patients Not Eligible for Transplant
SpainStudy of iberdomide alone or with drug combinations for patients with multiple myeloma: testing safety and effectiveness of different doses
FranceStudy on Iberdomide for Maintenance Therapy in Patients with Newly Diagnosed Multiple Myeloma After Stem Cell Transplantation
FranceStudy Comparing Lenalidomide, Bortezomib, Dexamethasone, Isatuximab, and Iberdomide for Newly Diagnosed Multiple Myeloma Patients Eligible for Stem Cell Transplant
SpainTell us about your condition – we search every trial in Europe and connect you with the right site.
